logo

For the Inventor, By the Inventor

London, United Kingdom

Mina Therapeutics Limited

USPTO Granted Patents = 16

% Expired Patents = 6.3


Forward Citations = 6

Loading Chart...
Loading Chart...

14 inventors (with patents filed for the assignee):

goldMedal Pål Sætrom (10 out of 10 patents)

silverMedal Hans E Huber (4 out of 6 patents)

bronzeMedal Markus Hossbach (3 out of 20 patents)

4.  Monika Krampert (3 out of 5 patents)

5.  David Blakey (3 out of 3 patents)

6.  Jon Voutila (3 out of 3 patents)

7.  Pal Saetrom (2 out of 6 patents)

8.  Vikash Reebye (2 out of 2 patents)

9.  Hans-Peter Vornlocher (1 out of 53 patents)

10.  Andreas Wagner (1 out of 1 patent)

11.  Robert Habib (1 out of 1 patent)

12.  Endre Bakken Stovner (1 out of 1 patent)

13.  Siv Anita Hegre (1 out of 1 patent)

14.  Pinelopi Andrikakou (1 out of 1 patent)

15.  Pal Saertrom (0 patent)


16 patents:

1. 11965163 - HNF4a saRNA compositions and methods of use (2024-04-23),
2. 11566246 - SIRT1-saRNA compositions and methods of use (2023-01-31),
3. 11447773 - Stabilized HNF4A saRNA compositions and methods of use (2022-09-20),
4. 11365414 - Methods of inducing insulin production (2022-06-21),
5. 11162099 - HNF4A saRNA compositions and methods of use (2021-11-02),
6. 10912790 - C/EBP alpha saRNA compositions and methods of use (2021-02-09),
7. 10774331 - Methods of inducing insulin production (2020-09-15),
8. 10704044 - Albumin production and cell proliferation (2020-07-07),
9. 10633659 - C/EBPα short activating RNA compositions and methods of use (2020-04-28),
10. 10202601 - C/EBPα short activating RNA compositions and methods of use (2019-02-12),
11. 9944930 - Albumin production and cell proliferation (2018-04-17),
12. 9885046 - Methods of inducing insulin production (2018-02-06),
13. 9745579 - Albumin production and cell proliferation (2017-08-29),
14. 9284553 - Albumin production and cell proliferation (2016-03-15),
15. 8916534 - Methods of inducing insulin production (2014-12-23),
Company Overview
Mina Therapeutics Limited is a biotechnology company based in London, specializing in the development of innovative therapies that harness the power of RNA to modulate gene expression. The company focuses on advancing treatments for various diseases by utilizing its proprietary platform to create RNA-based therapeutics. Mina Therapeutics aims to address unmet medical needs through its research in genetic medicine, positioning itself at the forefront of the evolving landscape of RNA therapeutics.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

16 Patents

#222 in London

#1,118 in United Kingdom

#37,868 in the World

London, GB
London, United Kingdom

Mina Therapeutics Limited

Forward Citations = 6

14 inventors:

goldMedal Pål Sætrom (10 out of 10 patents)

silverMedal Hans E Huber (4 out of 6 patents)

bronzeMedal Markus Hossbach (3 out of 20 patents)

4.  Monika Krampert (3 out of 5 patents)

5.  David Blakey (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Mina Therapeutics Limited. Retrieved from https://idiyas.com/company/mina-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…